Cargando…
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
An In Vitro Comparative Immunogenicity Assessment (IVCIA) assay was evaluated as a tool for predicting the potential relative immunogenicity of biotherapeutic attributes. Peripheral blood mononuclear cells from up to 50 healthy naïve human donors were monitored up to 8 days for T-cell proliferation,...
Autores principales: | Joubert, Marisa K., Deshpande, Meghana, Yang, Jane, Reynolds, Helen, Bryson, Christine, Fogg, Mark, Baker, Matthew P., Herskovitz, Jonathan, Goletz, Theresa J., Zhou, Lei, Moxness, Michael, Flynn, Gregory C., Narhi, Linda O., Jawa, Vibha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975389/ https://www.ncbi.nlm.nih.gov/pubmed/27494246 http://dx.doi.org/10.1371/journal.pone.0159328 |
Ejemplares similares
-
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
por: Joubert, Marisa K., et al.
Publicado: (2012) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016) -
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
por: Kuriakose, Anshu, et al.
Publicado: (2016) -
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
por: Krishna, Murli, et al.
Publicado: (2016)